-Evaluation of the Myositis disease activity assessment tool (MYOACT) and Myositis intention to treat activity index (MITAX) as prognostic tools.
Methods
Hospital records from Danish JDM patients (1977 -2005 were reviewed. The parameters of the MYOACT and MITAX were used for the database.
Results
53 patients were classified as JDM. The female:male ratio was 2:1, the mean age at disease onset was 7.1 years and the mean disease duration was 3.6 years. Most frequent symptoms at disease onset are displayed in Table 1 .
At the 5-years follow-up 34% were in remission, 30% had ongoing disease and disease-or treatment-induced damage was present in 36%. In the total follow-up period (2-30 years) 3 patients (6%) had died, 68% were in full remission, 13% had ongoing disease and 13% had unknown status.
Conclusion
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